Cure8 research brief
A formulation that increases oral absorption of quercetin and reduces inflammation in animal models could point toward new flavonoid-based therapies for ulcerative colitis, but findings are preclinical.
Researchers, clinicians focused on IBD drug delivery, and patients interested in emerging preclinical treatments
The authors prepared flexible quercetin nanocrystals (QUE-NCs) using an antisolvent precipitation method with geniposide and tested efficacy in a DSS-induced colitis mouse model and pharmacokinetics in rats.
In the preclinical models, QUE-NCs reduced markers of inflammation and oxidative stress, improved disease activity measures, and showed increased oral bioavailability versus raw quercetin. The paper presents validated HPLC quantification and basic biosafety assessments in the tested animals.
This is an abstract/full-text report of preclinical animal experiments with validated analytical methods; it does not provide human clinical data and should not be taken as evidence of clinical benefit in people.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
A common heart drug, verapamil, reduced disease signs in a mouse model of colitis and altered inflammation and the gut microbiota — suggesting a possible avenue for future IBD research. These are preclinical results, so...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
